10 / 22
Page 65
Notes:
conferenceseries
.com
Volume 5, Issue 5(Suppl)
J Child Adolesc Behav, an open access journal
ISSN: 2375-4494
Child Psychology 2017
September 28-29, 2017
September 28-29, 2017 Berlin, Germany
23
rd
International Conference on
Adolescent Medicine &
Child Psychology
Can gastroenterology change the therapeutic approach to autism? An innovative proposal for the study of the
causes of autism
1
Roberto Menicagli
and
2
Menicagli Laura
Romabiomed Research Lab
Irsccpoliclinic San Donato University Milan
S
everal studies demonstrated that many foods may provide many bioactive peptides into the gastrointestinal tract, as for example,
the beta-casomorphin-7, an opioid-like peptide produced by casein. Recent studies have established that the production of these
opioid peptides is experimentally associated with autism. Autism is a developmental disorder with a possible connection between
dietary components and triggering or worsening of symptoms. An altered intestinal permeability might allow absorption of
incompletely digested peptides (gluten and casein) that could produce opioid-like activity in the brain, causing significant changes in
behavior. It is also showed, that phenomenon, of the formation of the opioid peptides, strongly stimulates intestinal mucin production
in ex vivo and
in vitro
models, in particularly, these effects were associated with a higher expression of intestinal mucins (gel forming),
MUC2, the principal constituent of Gut Protective Layer. The Over Expression of MUC 2 ,contrary to what one might think, does not
strengthen the intestinal protective layer, but rather tends to altering the continuous layer, in a succession of bubbles, separated by
channels, which allow for greater permeability, facilitating the cycle of the opioid peptides and the free radicals The effect is twofold:
inhibition of nerve receptors, and formation of, cerebral micronuclei .The purpose of this study is to propose research, as NMR, for
with the imaging to evaluate, the biochemical process for inhibit the MUC2 Over–Expression, in autism, using for example enzyme
as the sialidase.
Biography
Roberto Menicagli has completed his PhD from Milan University. He has completed his Postdoctoral studies in Biochemistry and Molecular Genetics at Milan
University. He is the Director of Roma Biomed Research Lab, a private medical service organization. He has published more than 20 papers in reputed journals
and he is also the principal author of four international patents, in the field of the environment, and biomarkers, and has been serving as an Editorial Board Member
of two magazines concerning the medical sciences.
menicagli@libero.itRoberto Menicagli et al., J Child Adolesc Behav 2017, 5:5(Suppl)
DOI: 10.4172/2375-4494-C1-003